این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Middle East Journal of Cancer، جلد ۱۴، شماره ۲، صفحات ۲۹۲-۲۹۹
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی The Efficacy and Safety of Captopril in Preventing Capecitabine-induced Hand-foot Syndrome: A Randomized Double-blinded Placebo-controlled Clinical Trial
چکیده انگلیسی مقاله Background: Hand-foot syndrome (HFS) is a prevalent skin reaction to cytotoxic systemic therapy, mainly Capecitabine. The present study aimed to determine etiologies of HFS in addition to its prevention in colorectal cancer patients with Capecitabine-containing chemotherapy regimen. Method: In this randomized double-blinded study, we recruited 66 eligible patients. The first 33 patients received 25 mg captopril twice daily, while the other 33 were given two placebo tablets. Results: All the patients were assessable for safety and efficacy. Captopril demonstrated a favorable safety profile. The participants in the two groups did not have any significant differences in terms of the median age and the level of hemoglobin (P = 0.45, P = 0.06, respectively). However, the CEA tumor marker was significantly higher in those with HFS (P < 0.05). The incidence of HFS in men and women were 8 (18.6%) and 3 (13%) cases, respectively, and the patients’ sex did not affect the incidence of this syndrome (P = 0.73). Furthermore, according to the stage of colorectal cancer, the difference between the two groups was significant (P < 0.05). Meanwhile, there were no significant differences concerning the grade of colorectal cancer (P = 0.2). Conclusion: The results herein revealed that administration of captopril in colorectal cancer patients with Capecitabine-containing chemotherapy regimen reduced the symptoms and incidence of HFS. On the other hand, CEA tumor marker and the stage of colorectal cancer were in correlation with incidence of HFS.
کلیدواژه‌های انگلیسی مقاله Hand-foot syndrome, Capecitabine, Captopril
نویسندگان مقاله Mahnaz Roayaei |
Radiation Oncology Department, Isfahan University of Medical Sciences, Isfahan, Iran

Nooshin Nazeminezhad |
Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Nadia Najafizade |
Radiation Oncology Department, Isfahan University of Medical Sciences, Isfahan, Iran

Mehran Sharifi |
Hematology Oncology Department, Isfahan University of Medical Sciences, Isfahan, Iran

نشانی اینترنتی https://mejc.sums.ac.ir/article_48767_ebef4decaf0a611259e2fb7e51a26aaa.pdf
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات